Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial.
about
Targeting PI3K in cancer: impact on tumor cells, their protective stroma, angiogenesis and immunotherapyHormonoresistance in advanced breast cancer: a new revolution in endocrine therapy.Fulvestrant in advanced breast cancer: evidence to date and place in therapy.Molecular Biomarkers for Prediction of Targeted Therapy Response in Metastatic Breast Cancer: Trick or Treat?Circulating-free DNA Mutation Associated with Response of Targeted Therapy in Human Epidermal Growth Factor Receptor 2-positive Metastatic Breast CancerApproaches to identify kinase dependencies in cancer signalling networks.The Phosphatidylinositol 3-kinase Pathway as a Potential Therapeutic Target in Bladder Cancer.Role of fulvestrant in the treatment of postmenopausal metastatic breast cancer patients.PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment.Fulvestrant plus targeted agents versus fulvestrant alone for treatment of hormone-receptor positive advanced breast cancer progressed on previous endocrine therapy: a meta-analysis of randomized controlled trials.Overcoming aromatase inhibitor resistance in breast cancer: possible mechanisms and clinical applications.Neoadjuvant Trials in ER+ Breast Cancer: A Tool for Acceleration of Drug Development and Discovery.Biological characterization of SN32976, a selective inhibitor of PI3K and mTOR with preferential activity to PI3Kα, in comparison to established pan PI3K inhibitors.Combining "Bottom-up" and "Top-down" Approaches to Assess the Impact of Food and Gastric pH on Pictilisib (GDC-0941) Pharmacokinetics.Emerging data on improving response to hormone therapy: the role of novel targeted agents.Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, plaA Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of Pictilisib in Combination with Erlotinib in Patients with Advanced Solid Tumors.Autophagy promotes escape from phosphatidylinositol 3-kinase inhibition in estrogen receptor-positive breast cancer.Estrogen Receptor-Positive Breast Cancer: Exploiting Signaling Pathways Implicated in Endocrine Resistance.Strategies and Progress of Endocrine Therapy for Patients with Metastatic Breast Cancer.Impact of multi-gene mutational profiling on clinical trial outcomes in metastatic breast cancer.PI3K/mTOR Inhibitors in the Treatment of Luminal Breast Cancer. Why, When and to Whom?Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer.PI3K inhibition to overcome endocrine resistance in breast cancer.Efficacy of PI3K/AKT/mTOR pathway inhibitors for the treatment of advanced solid cancers: A literature-based meta-analysis of 46 randomised control trials.New agents for the management of resistant metastatic breast cancer.Profile of buparlisib and its potential in the treatment of breast cancer: evidence to date.Therapeutically targeting tumor microenvironment-mediated drug resistance in estrogen receptor-positive breast cancer.NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast Cancer.Clinically Observed Estrogen Receptor Alpha Mutations within the Ligand-Binding Domain Confer Distinguishable Phenotypes.A Review of Fulvestrant in Breast Cancer.Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer.Recent Advances in the Treatment of Breast Cancer.High-dose fulvestrant as third-line endocrine therapy for breast cancer metastasis to the left kidney: A case report and literature review.The impact of PI3K inhibitors on breast cancer cell and its tumor microenvironment.Signaling pathways and steroid receptors modulating estrogen receptor α function in breast cancerClinical utility of fulvestrant in the treatment of breast cancer: a report on the emerging clinical evidencePhase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast CancerComparison of interleukin-2-inducible kinase (ITK) inhibitors and potential for combination therapies for T-cell lymphomaThe Divergent Function of Androgen Receptor in Breast Cancer; Analysis of Steroid Mediators and Tumor Intracrinology
P2860
Q29248893-0586BA00-0DF4-400E-866E-9C583F8D29F8Q33656801-1F3C0656-E258-4A71-A302-7A18DC866A22Q33887675-2A96B2B3-5DC6-4FF9-80DB-A13E803E103DQ37631514-0B1B99C7-C00B-4677-852D-09FA679AFFA1Q37684125-36AC9717-B6F2-4A94-9381-B03BFC98179DQ38660465-EC35CE05-3BC7-45BC-8FAE-D973C660BBB4Q38694934-EDD132DB-AC12-4224-BDEB-7FB5D7EFCD57Q38933237-03DAA0BD-3876-4701-AF6A-7B1907898266Q39023175-5AD7990F-30AB-4DF5-AFB4-AD7730DA5FE4Q39190569-05009DE8-A9A6-47E2-809C-FC619E7F1DAEQ39227889-83F3609C-BD27-45E2-9C5B-82738E0F29F1Q39299810-BA85E5D8-A5B7-432B-87F3-3704D5B4C1DEQ41471269-A3A26BC0-C363-4227-BAE3-E3A6F9A77D8DQ45977183-17875A5B-20AB-430C-A53F-41B432B78DD9Q46537162-9C9D399C-929C-4B6E-8FD5-906E5453B734Q46626206-BB595DA0-4EA7-46F9-ACC1-0ED8820EFE66Q46946333-84699196-187A-4971-9C75-79669C536481Q47414919-0B5E7B34-AB56-4767-858A-727C1548E5B3Q47551153-29FE1DA4-D670-4357-8EDB-62189D8B1397Q47561979-89947260-1BC7-4F57-AA12-82BFEACC1921Q47564750-F4200C3C-CDD5-4A91-8E13-B82B5E726D1DQ47578323-C6F5390F-9676-4837-BF83-2AB9C17FB074Q47584016-CBFDC30A-A9C2-4482-8F57-B12DEC5E9DEFQ47776273-155D3CAA-A31C-4DB6-8412-653F7D8304FAQ48097821-093B438D-8276-4C36-BE1E-E48167424C23Q48240854-5AFCC24B-FC9A-4418-8D3E-D2C869F45335Q49478004-902075E8-DF0F-4A95-8BAD-30AA7F74CE14Q50048638-4744DF35-BD46-401E-A1FD-C1CB59C7521AQ50093673-B6E96C5F-1D66-45D6-99B4-0C28394CCAB9Q50147171-4CBE9A77-252D-4C46-8629-01B8BFB5A929Q53733893-459DDAC6-13D8-465D-8B01-5B341B472561Q55310990-3102A4DB-16B6-4C0A-860E-F42BDAAC2A05Q55353691-7517DC26-550A-44BD-98A9-F426F3CAE60AQ55427632-01FD5BC4-EEBF-4F95-BD25-049EB9CCC7EFQ55435506-F16EEAF8-F4F3-446C-84F9-65E8513F1ADFQ57106904-E9270E02-CCE4-47E9-A0E0-6AECB87787F9Q57107345-4024B91A-390E-4C90-AFD3-C954FC65E16EQ57391370-470BACFD-21FA-484D-B199-C1AA8E9B5AB2Q58705889-B258D808-1A4D-470D-8DFB-8D020872D0C2Q58707374-1A6E8B30-E5F6-4E2A-95C6-CA607B9580FD
P2860
Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial.
description
2016 nî lūn-bûn
@nan
2016 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Pictilisib for oestrogen recep ...... ebo-controlled, phase 2 trial.
@ast
Pictilisib for oestrogen recep ...... ebo-controlled, phase 2 trial.
@en
type
label
Pictilisib for oestrogen recep ...... ebo-controlled, phase 2 trial.
@ast
Pictilisib for oestrogen recep ...... ebo-controlled, phase 2 trial.
@en
prefLabel
Pictilisib for oestrogen recep ...... ebo-controlled, phase 2 trial.
@ast
Pictilisib for oestrogen recep ...... ebo-controlled, phase 2 trial.
@en
P2093
P2860
P1433
P1476
Pictilisib for oestrogen recep ...... cebo-controlled, phase 2 trial
@en
P2093
Andres Forero-Torres
Bohuslav Melichar
Denise A Yardley
Edith A Perez
Eric Winer
Gallia Levy
Ian E Krop
Ingrid A Mayer
Jiaheng Qiu
P2860
P304
P356
10.1016/S1470-2045(16)00106-6
P577
2016-05-04T00:00:00Z